Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Revenue (2019 - 2025)

Historic Revenue for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to $14.3 million.

  • Keros Therapeutics' Revenue rose 357577.32% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.7 million, marking a year-over-year increase of 3779831.03%. This contributed to the annual value of $3.6 million for FY2024, which is 225099.34% up from last year.
  • Per Keros Therapeutics' latest filing, its Revenue stood at $14.3 million for Q3 2025, which was up 357577.32% from $18.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Revenue ranged from a high of $211.2 million in Q1 2025 and a low of -$1000.0 during Q1 2021
  • In the last 5 years, Keros Therapeutics' Revenue had a median value of $388000.0 in 2024 and averaged $21.8 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 180010000.0% in 2022, then surged by 202727.27% in 2024.
  • Quarter analysis of 5 years shows Keros Therapeutics' Revenue stood at $17.9 million in 2021, then grew by 0.56% to $18.0 million in 2022, then tumbled by 99.21% to $143000.0 in 2023, then skyrocketed by 2027.27% to $3.0 million in 2024, then soared by 368.84% to $14.3 million in 2025.
  • Its Revenue was $14.3 million in Q3 2025, compared to $18.2 million in Q2 2025 and $211.2 million in Q1 2025.